Shanghai Hile Bio-Tech

Shanghai Hali was named a ‘Science and Technology Little Giant’ by the Fengxian District Science Bureau in December 2007.

Shanghai Hali’s PRRSV (blue-ear disease) live vaccine project won Shanghai’s 2007 ‘Imported Technology Absorption and Innovation’ award.

Shanghai Hali supplied 183,000 mL of highly pathogenic porcine blue-ear disease vaccine to Shanghai’s animal disease command in July 2007, followed by 1 million mL on July 12. The company later provided 600,000 mL monthly.

Shanghai Hali Biotech was an approved producer of veterinary biologics in Shanghai and a key base for animal epidemic prevention. In 2024, it shifted focus to human health diagnostics and oral tissue repair materials through asset restructuring.

Shanghai Hali Biotech provides contact information for its human health diagnostics and oral tissue repair materials businesses.

Shanghai Hile Bio-Technology Co., Ltd. reports **CNY 239.04 million in sales** for the first nine months of 2026, up from **CNY 149.74 million** in the same period last year. The company’s net income rises to **CNY 21.76 million**, compared to **CNY 20.33 million** year-over-year. The results reflect growth in revenue and sustained profitability during the period.

Oct 2026MarketScreenerNews article

Shanghai Hile Bio-Technology Co. Ltd. (XSSC:603718) has been excluded from the S&P Global BMI Index. The company operates in the biotechnology sector and is listed on Chinese stock exchanges. This change reflects adjustments in the index’s composition, though no specific reasons are provided in the report.

May 2026MarketScreenerNews article

Vietnam’s Ministry of Health approves Shanghai Hile Bio-Technology’s absorbable collagen membrane for dental reconstruction. The product targets tooth loss treatment and is now cleared for use in Vietnam. The approval follows a regulatory filing with the Shanghai Stock Exchange.

Mar 2026MarketScreenerNews article

Shanghai Hile Bio-Technology Co., Ltd. acquires an additional 41% stake in Shaanxi Reshine Biotech Co. Ltd. from Maylion Management Limited for approximately CNY 400 million. The transaction, finalized in November 2025, increases Shanghai Hile’s ownership to 96% through a cash payment of CNY 399.3 million. The deal strengthens Shanghai Hile’s control over Shaanxi Reshine’s equity.

Dec 2025MarketScreenerNews article